Lung cancer drug lorbrena under Post-Market safety review
NCT ID NCT03844464
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 29 times
Summary
This study monitored 1,290 patients with non-small cell lung cancer who were already taking the drug Lorbrena after it was approved. The goal was to track side effects, especially brain and liver problems. No new treatment was given; it was purely an observation of real-world safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
3-22-7, Yoyogi, Shibuya-ku
Tokyo, 151-8589, Japan
Conditions
Explore the condition pages connected to this study.